✦ LIBER ✦

Sa1319 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis (S-USIIT-01)

✍ Scribed by Hassanein, Tarek; Box, Terry D.; Tong, Myron J.; Pozza, Renee; Rossaro, Lorenzo; Glenn, Jeffrey; Cheung, Ramsey C.; Hemaidan, Ammar; He, Yingchun; Sheng, Yu-cheng; Barakat, Fatma; Behling, Cynthia; Liu, Chenghai; Liu, Ping; Vierling, John M.

Book ID: 122128169
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 94 KB
Volume: 146
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(14)60921-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II randomized, double-blind, pla

A phase II randomized, double-blind, placebo-controlled multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin: Paul J Pockros, John G McHutchison, Scripps Clinic, La Jolla, CA; Chris O'Brien, University of Miami, Miami, FL; Myron Tong, Huntingon Medical Research Institute, Pasadena, CA; Coleman Smith, Minnesota Clinical Research Center, St. Paul, MN; Vinod Rustgi, Metropolitan Research Group, Fairfax, VA; Robert L Carithers, University of Washington Medical Center, Seattle, WA; Elizabeth Olek, Genetics Institute, Cambridge, MA

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB